Metabonomic assessment of vasculitis in rats

被引：48

作者：

Robertson D.G. ^{[1
]}

Reily M.D. ^{[1
]}

Albassam M. ^{[1
]}

Dethloff L.A. ^{[1
]}

机构：

[1] Department of Drug Safety Evaluation, Pfizer Global Research and Development, Ann Arbor

来源：

Cardiovascular Toxicology | 2001年 / 1卷 / 1期

关键词：

Metabonomics; NMR; vasculitis; CI-1018; PDE-4 inhibition;

D O I：

10.1385/CT:1:1:07

中图分类号：

学科分类号：

摘要：

The vasculitides are a heterogeneous group of lesions characterized by inflammation and necrosis of the vascular wall and have proven to be a disconcerting dilemma in the development of several classes of therapeutics. Metabonomics is an emerging technology having great potential for rapid noninvasive assessment of toxicity in vivo and providing identification of peripheral surrogate markers of toxicity. Metabonomic evaluation of CI-1018, a selective type 4 phosphodiesterase inhibitor associated with vasculitis in rats, was undertaken. Two experiments were performed in which CI-1018 was administered for up to 4 d to groups of male Wistar rats at doses up to 3000 mg/kg. Urine was collected from all animals pretest and daily for metabonomic analysis. Eleven of 38 CI-1018-treated animals were found to have vascular injury of varying severity at doses = or > 750 mg/kg. Principal component analysis produced a clear pattern separation among 8 of 11 animals with lesions and 36 of 37 animals without lesions in samples collected on d 3 or 4. These data demonstrate that the metabonomics approach has significant potential for developing a noninvasive method for identifying vasculitis in rats. It remains to be seen if urinary analyte patterns identified in this study are reproducible and whether a biomarker pattern for vasculitis can be established.

引用

页码：7 / 19

页数：12

共 96 条

[1]

Bloch D.A.(1990)The American College of Rheumatology 1990 criteria for the classification of vasculitis—patients and methods Arthritis Rheum. 33 1068-1073

[2]

Michel B.A.(1990)The American College of Rheumatology 1990 criteria for the classification of vasculitis—summary Arthritis Rheum 33 1135-1136

[3]

Hunder G.G.(1995)Neurological manifestation of vasculitis: update on immunopathogenic mechanisms and clinical features Ann Neurol. 37 S131-S141

[4]

McShane D.J.(1998)Central nervous system vasculitis J Neurol. Sci. 153 159-171

[5]

Arend W.P.(1990)The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis Arthritis Rheum 33 1108-1113

[6]

Calabrese L.H.(1985)Cutaneous drug reactions: pathogenesis and clinical classification J. Am. Acad. Dermatol. 13 167-179

[7]

Fries J.F.(1978)The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations Ann. Intern. Med. 89 600-676

[8]

Hunder G.G.(1991)Drug induced vasculitides Baillieres Clin. Rheumatol. 5 119-138

[9]

Bloch D.A.(1989)Identification of an autoantibody to vascular endothelial cell-specific antigens in patients with systemic vasculitis Am. J. Med. 87 74-80

[10]

Michel B.A.(1988)Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis N. Engl. J. Med. 318 1651-1657

← 1 2 3 4 5 6 7 8 9 10 →